Cardiovascular disease and lipid-regulating drugs

Abstract

Cardiovascular disease (CVD) accounts for approximately one-third of deaths in England and Wales, and its associated morbidity cost the NHS in England alone almost £8 million in 2010 (National Institute for Health and Care Excellence (NICE), 2014). Modifiable risk factors include hypertension, smoking and raised cholesterol level. The Joint Formulary Committee (2016) recommends the preventative use of lipid-regulating drugs where there is a high risk of developing CVD and to prevent recurrence in those with recognised CV